What Policor Treats: Main Uses and Benefits

Policor (Cilostazol) is commonly used to address symptoms associated with Intermittent Claudication. This medication is applied in addressing the overall functional mobility restriction caused by Peripheral Arterial Disease (PAD).

The drug's primary relevance is for managing exertion-related leg pain, cramping, or discomfort that occurs when walking, as well as the resulting limitations in physical activity. It is used across conditions characterized by symptoms that interfere with daily functioning and become more noticeable during physical effort.

“The therapeutic goal is linked to increasing walking distance for patients experiencing symptomatic claudication.”

Policor assists with easing the overall symptomatic burden in this chronic circulatory context. This supports the patient during difficult episodes of heightened discomfort and may contribute to improved day-to-day comfort and stability.

Quick Fact: Relief for Exertion-Related Pain
Policor is commonly used to help with muscle pain and cramping that is specifically brought on by physical activity and creates noticeable interference with walking distance.

Policor (Cilostazol) use is defined by specific population eligibility rules documented by regulatory authorities. The medication is permitted for use in adults without contraindications, and older adults do not require special dosage adjustments based on age alone.

---

Absolute Non-Eligibility (Contraindications)

The medicine must not be used in patients with:

• Heart Failure of any severity.
• Severe Renal Impairment (creatinine clearance leq 25 ml/min) or Moderate or Severe Hepatic Impairment.
• Pregnancy (formally contraindicated in European labeling).
• A known predisposition to bleeding, including recent haemorrhagic stroke (within six months).
• Unstable angina pectoris, Myocardial Infarction, or coronary intervention within the last six months.
• A history of severe tachyarrhythmia or if the patient is taking two or more additional antiplatelet or anticoagulant agents.

---

Use Not Established or Not Recommended

Pediatric Use: Safety and efficacy have not been established in children.

Lactation: Use is not recommended during breastfeeding.

Restricted Use: Caution and close monitoring are required for patients with stable coronary disease or certain forms of atrial or ventricular ectopy.

Interactions with other medicines and products

The official interaction profile for Policor (Cilostazol) is defined by its metabolic clearance and its pharmacological class, which results in specific, mandatory co-administration restrictions documented by regulatory authorities.

---

Official Interaction Constraints

• Metabolic Interactions (↑ Exposure): Co-administration with strong or moderate CYP3A4 inhibitors (e.g., Ketoconazole, Erythromycin) or CYP2C19 inhibitors (e.g., Omeprazole) significantly increases the systemic exposure of Cilostazol or its active metabolite. This pharmacokinetic outcome requires a mandatory adjustment of the prescribed amount.
• Pharmacodynamic Risk (↑ Bleeding): Concurrent use with other antiplatelet agents (such as Aspirin or Clopidogrel) or Anticoagulants may result in a pharmacodynamic additive effect. This effect officially increases the documented risk of bleeding and necessitates close monitoring.
• Food/Substance Restriction: Consumption of grapefruit or grapefruit juice is formally advised against. This is due to a documented increase in the drug's maximum plasma concentration (Cmax) by approximately 50%.
• Disease Contraindication: The use of Policor is formally contraindicated in patients with Heart Failure of any severity, as this drug class has been associated with decreased survival in this population.

---

Population-Specific Notes

Dosing recommendations are officially unavailable for patients with severe renal impairment or moderate to severe hepatic impairment due to documented alterations in drug disposition or a lack of study data in these populations.

Policor (Cilostazol) works through the selective inhibition of the Phosphodiesterase Type 3 ( PDE3) enzyme, a process that simultaneously modulates two core physiological functions: vascular tone and platelet activity.

Enzyme-Mediated Signal Amplification via cAMP

The drug's action begins at the molecular level by blocking the PDE3 enzyme, which normally breaks down the crucial cellular messenger, cyclic AMP ( cAMP). This inhibition causes an increase in cAMP concentration inside two primary cell types: vascular smooth muscle cells ( VSMCs) and platelets. This mechanism is the singular source of the drug's self-complementary physiological function.

Dual Physiological Effect: Vasodilation and Anti-Aggregation

In VSMCs, the amplified cAMP signal leads to the relaxation of the muscle tissue, resulting in arterial widening (vasodilation) and a reduction in peripheral vascular resistance. In platelets, the same cAMP increase stabilizes the cell, actively suppressing its response to aggregating triggers and thereby achieving an antiplatelet effect. These two effects act in coordination to alter the flow dynamics and increase the perfusion capacity of distal tissues.

How to Use Policor

The administration of Policor, which contains Cilostazol, follows a standardized protocol to ensure consistent usage. The medication is an oral tablet and must be administered by mouth.

---

Standard Regimen and Timing

Usage Parameter	Official Instruction
Route of Administration	Oral
Standard Dosing	100 mg
Frequency	Twice daily (b.i.d.)
Timing Relative to Meals	Must be taken on an empty stomach, specifically 30 minutes before or 2 hours after breakfast and the evening meal.

---

Contextual Usage Principles

Policor is typically used as part of a long-term plan, but the administration protocol mandates a specific duration pattern. The effects of the medicine are generally evaluated after a course of approximately three months. If a patient shows no improvement in symptoms after this period, the course of administration should be discontinued.

For situations involving co-administration with other medicines, specific dosage rules apply. When Policor is taken alongside certain strong or moderate inhibitors of the CYP3A4 or CYP2C19 enzymes, the administration dose is reduced to 50 mg twice daily.

Regarding missed timing, if a dose is not taken at the scheduled time, the subsequent dose should be taken at the next regular time; the patient should not take an extra or double dose to compensate for the missed administration.

Research evidence / Overview of studies for Policor (Cilostazol)

---

Evidence for Use in Symptomatic Intermittent Claudication

The primary evidence base for Policor was developed using numerous short-term Randomized Controlled Trials (RCTs), often lasting three to six months. These studies were applied in research exploring how symptoms change over time for individuals with symptomatic Intermittent Claudication (IC), which is a condition marked by functional limitations. Systematic reviews and meta-analyses—which combine data from multiple RCTs—were also used to assess the drug.

Research examined outcomes related to physical discomfort that limits daily functioning, specifically focusing on the distance people could walk without pain and the maximum distance they could walk on a treadmill test. These studies were conducted during periods of increased symptom activity in adults who had stable, diagnosed artery disease in their legs. Studies report that the difference in walking distance measurements between the groups receiving the medication and the groups receiving a placebo was monitored.

---

How Policor Was Studied: Placebo and Functional Measures

The main study designs used were double-blind, placebo-controlled trials. This means that neither the patients nor the researchers knew who was receiving Policor and who was receiving the placebo. This method is important for making sure that any observed changes measured during the study period may be associated with the medication and not to expectation.

Studies focused on measurable functional outcomes, which included specific assessments on a treadmill to quantify walking ability. Researchers monitored how symptoms evolved in the observed populations by measuring both the distance until the first onset of pain (pain-free walking) and the total distance walked before stopping due to discomfort.

---

Long-Term Research and Durability of Response

While many pivotal trials exploring changes in walking distance had follow-up durations that were limited to six months, researchers have also explored the drug in longer-term studies. However, the existing evidence derived from these settings provides limited information for long-term outcomes, particularly regarding whether the use of the medication is associated with a change in the risk of major cardiovascular events, such as heart attack or stroke. Long-term effects on these serious outcomes are not fully established, and certainty remains low in this area of research.

Key Studies & References

1. Effects of cilostazol on cardiovascular events in patients with peripheral artery disease: a controlled trial (CASTLE Study)
2. NICE Guideline: Peripheral arterial disease: diagnosis and management

Common questions about Policor (FAQ)

---

Q: How quickly should I expect to feel a difference after starting Policor?

A: Official product information indicates that some patients may begin to see benefits within two to four weeks of starting therapy. However, the full therapeutic effect often requires consistent use for up to 12 weeks (3 months). If no improvement is observed after this period, official guidance in the product labeling suggests that discontinuation should be considered by a healthcare provider.

---

Q: Does taking Policor require regular blood tests?

A: Official regulatory labeling indicates that periodic monitoring of certain blood cell counts, specifically platelet and white blood cell counts, is generally recommended. This recommendation is based on the potential, though uncommon, risk of serious effects on the blood and lymphatic system associated with the medication.

---

Q: Does Policor affect my ability to drive or operate machinery?

A: Because dizziness is listed as a common side effect of Policor, individuals should use caution when performing activities that require full concentration, such as driving or operating heavy machinery, if they feel light-headed. This is a general safety precaution noted in official information.

---

Q: Can Policor be split or crushed if I have trouble swallowing pills?

A: The official labeling does not contain instructions that the tablet can be split or crushed, as the product is intended to be swallowed whole. Any alteration to the tablet should only be done under the specific guidance of a healthcare professional to ensure the medicine works as intended and is absorbed correctly.

---

Q: What happens if I take Policor with food, since it is supposed to be taken on an empty stomach?

A: The medicine is generally prescribed to be taken on an empty stomach to manage its absorption. Official studies show that taking Policor with food, particularly a high-fat meal, increases the amount of drug absorbed into the bloodstream. This increased systemic exposure has been associated with a potential for an increased frequency of side effects.

---

Q: What kind of monitoring is needed after starting Policor?

A: Official monitoring recommendations include assessing the risk of increased bleeding and evaluating blood cell counts on a regular basis. Additionally, assessment for changes in heart rate may be recommended for patients with a history of certain underlying heart conditions.

---

Q: How does Policor compare to generics, is it the same active ingredient?

A: Policor is the brand name for the active ingredient Cilostazol. Generic versions contain the exact same active pharmaceutical ingredient. Regulatory agencies approve generic products based on evidence that they perform and work in the same manner as the brand-name product.

---

Q: What are the signs that Policor might not be working for me?

A: The medicine is prescribed with the goal of improving functional capacity, most often measured by an increase in walking distance. Official guidelines state that if there is no documented improvement in symptoms after three months of therapy, discontinuation of the medication is typically considered by the prescribing professional.

---

Q: Does Policor affect athletic performance or exercise tolerance?

A: Clinical studies primarily focused on measuring the medicine's effect on functional capacity related to its indication, such as an increase in pain-free walking distance. These outcomes indicate a documented improvement in functional walking capacity, but the product labeling does not make direct claims about 'athletic performance' outside of its use for Intermittent Claudication.

---

Q: How does Policor affect cholesterol levels?

A: Official clinical pharmacology information indicates that Cilostazol has documented effects on lipids (fats in the blood). Studies reported that the use of this medicine resulted in a reduction in triglycerides and an increase in HDL-cholesterol (often referred to as 'good' cholesterol) compared to placebo.

---

Q: Does Policor interact with common over-the-counter pain relievers like ibuprofen?

A: Official interaction warnings recommend caution when using Policor with other antiplatelet agents, a category that includes non-prescription Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) such as ibuprofen. The concurrent use of these agents may be associated with an increased pharmacodynamic risk of bleeding.

---

Q: Is it better to take Policor in the morning or at night?

A: The official administration instructions specify that the medicine should be taken twice daily, precisely 30 minutes before or 2 hours after both breakfast and the evening meal. The focus of the instruction is on the timing relative to the food intake for optimal absorption, rather than a preference for morning versus night.

Storage and Disposal of Policor (Cilostazol)

Policor tablets must be maintained under specific conditions to ensure stability. The medicine should be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F), and must be protected from excess heat and moisture.

Handling and Security

The tablets should be kept in the original container, which must remain tightly closed when not in use. It is a mandatory requirement to keep this medicine out of the sight and reach of children.

Disposal Requirements

Do not use the medicine past the expiry date printed on the packaging. To protect the environment, unused or expired Policor must not be thrown away in household waste or flushed down the toilet. Patients should consult a pharmacist or follow local regulations and official drug take-back programs for proper disposal.